Ark Invest Just bought These Bionano Genomics Stocks
The main focus lies on gene editing combined with some other biotech stocks. Cathie wood was saying that the biggest upside is going to come from genomic space. That's because the convergence of DNA editing, artificial intelligence, and gene therapies, importantly CRISPR gene editing, is going to cure disease
group of blood disorders typically inherited from a person's parents were there is protein pound in the red blood cells which shouldn’t be the case. They have been filing a request to the FDA to begin the 1/2 study of EDIT-301 in treating sickle cell disease.
Another biotech stock more focused on helping people around the world with CRISPR gene editing. HIV and poliovirus are such viruses
75.7 million people have become infected with HIV since the start of the epidemic so of course there's still a big market for this stock.
Older gene-editing tools take months to design a single, customized protein at a cost of more than $1,000 CRISPR can be reprogrammed to target multiple genes coming at a cost of $65 plus shipping.
This is the largest genomic holding of the ArkG ETF at this point it holds about $20,016,038 shares each with a total value of $543,035,110. Now let’s do a quick dive over to their quarterly analysis and see what we can find. Founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation
????Sign up for TubeBuddy to improve SEO of your YouTube videos https://www.tubebuddy.com/StealthWealth
DISCLAIMER - Any advice given in on my channel and videos is for information purposes only, and does not act as financial advice. Your financial decisions are your full responsibility, and if you are in any doubt, please contact a Finance adviser before undertaking any investment with your money or change to your financial activities.
The main focus lies on gene editing combined with some other biotech stocks. Cathie wood was saying that the biggest upside is going to come from genomic space. That's because the convergence of DNA editing, artificial intelligence, and gene therapies, importantly CRISPR gene editing, is going to cure disease
group of blood disorders typically inherited from a person's parents were there is protein pound in the red blood cells which shouldn’t be the case. They have been filing a request to the FDA to begin the 1/2 study of EDIT-301 in treating sickle cell disease.
Another biotech stock more focused on helping people around the world with CRISPR gene editing. HIV and poliovirus are such viruses
75.7 million people have become infected with HIV since the start of the epidemic so of course there's still a big market for this stock.
Older gene-editing tools take months to design a single, customized protein at a cost of more than $1,000 CRISPR can be reprogrammed to target multiple genes coming at a cost of $65 plus shipping.
This is the largest genomic holding of the ArkG ETF at this point it holds about $20,016,038 shares each with a total value of $543,035,110. Now let’s do a quick dive over to their quarterly analysis and see what we can find. Founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation
????Sign up for TubeBuddy to improve SEO of your YouTube videos https://www.tubebuddy.com/StealthWealth
DISCLAIMER - Any advice given in on my channel and videos is for information purposes only, and does not act as financial advice. Your financial decisions are your full responsibility, and if you are in any doubt, please contact a Finance adviser before undertaking any investment with your money or change to your financial activities.
- Category
- Crypto Trading
- Tags
Be the first to comment
